Tenax Therapeutics, INC 8-K filings

Tenax Therapeutics announced topline results from its Phase 3 LEVEL trial of TNX-103 for PH-HFpEF, which did not meet its primary endpoint for improving 6-minute walk distance.

Tenax Therapeutics announced its second quarter 2026 financial results, highlighting a strong cash position and providing an update on its pivotal Phase 3 LEVEL clinical trial, with topline data anticipated in August 2026.

Tenax Therapeutics will present results from its Phase 3 LEVEL clinical trial at the European Society of Cardiology (ESC) Congress 2026, with topline data expected in August 2026.

Tenax Therapeutics, Inc. has entered into a definitive Supply Agreement with Orion Corporation for its orally administered levosimendan product, alongside a Sixth Amendment to their existing License Agreement.

Tenax Therapeutics, Inc. has amended employment agreements for key executives, establishing severance and change-in-control benefits.

Tenax Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Tenax Therapeutics reported Q1 2026 financial results, highlighting progress in its Phase 3 LEVEL study for TNX-103 and strengthening its leadership team.

Tenax Therapeutics announced the appointment of Thomas R. Staab, II as its new Chief Financial Officer, effective May 11, 2026, replacing interim CFO Thomas A. McGauley.

Tenax Therapeutics' Chief Medical Officer, Dr. Stuart Rich, will transition to a four-day work week with a prorated salary, effective January 1, 2026.

Tenax Therapeutics announced its LEVEL Phase 3 trial is well-powered and initiated a second global Phase 3 study for TNX-103 in PH-HFpEF patients.

Tenax Therapeutics reported Q3 2025 financial results, highlighted progress in its Phase 3 LEVEL study, and announced a key European patent grant for TNX-103.

Tenax Therapeutics announced the European Patent Office's intention to grant a patent for TNX-103 (oral levosimendan) for pulmonary hypertension with heart failure with preserved ejection fraction, extending protection in Europe through at least 2040.

Tenax Therapeutics expanded its license agreement with Orion Corporation, gaining exclusive worldwide rights for orally-administered levosimendan products and manufacturing capabilities.

Tenax Therapeutics reported its second quarter 2025 financial results, highlighting ongoing progress in its Phase 3 LEVEL study and plans to initiate a second global Phase 3 study, LEVEL-2, for PH-HFpEF.

Tenax Therapeutics, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where key proposals including officer exculpation, director elections, and executive compensation votes were decided.

Tenax Therapeutics announces its Q1 2025 financial results and provides an update on the Phase 3 LEVEL study of TNX-103 in PH-HFpEF, targeting enrollment completion around year-end 2025 and topline data in mid-2026, while also planning to initiate a second Phase 3 study, LEVEL-2, this year.

Tenax Therapeutics reports financial results for 2024 and provides a corporate update, highlighting successful private placements totaling $125 million to support the development of TNX-103 for PH-HFpEF and fund operations through 2027.

Tenax Therapeutics announces a $25 million private placement to fund Phase 3 clinical trials and general corporate purposes, extending its cash runway through 2027.

Tenax Therapeutics has appointed Thomas A. McGauley as Interim Chief Financial Officer, effective December 2, 2024, replacing Lawrence R. Hoffman.

Tenax Therapeutics announced its third quarter 2024 financial results, highlighted by a $100 million private placement and continued progress in its Phase 3 LEVEL study for levosimendan.

Tenax Therapeutics stockholders approved an amendment to the 2022 Stock Incentive Plan, increasing the number of shares authorized for issuance by 7,935,912.

Tenax Therapeutics announced second quarter 2024 financial results, highlighted by a $100 million private placement and progress in their Phase 3 clinical trial for levosimendan.

Tenax Therapeutics has successfully closed a $100 million private placement, which will be used to accelerate the development of its oral levosimendan program for pulmonary hypertension due to heart failure with preserved ejection fraction.

Tenax Therapeutics has successfully raised approximately $100 million through an oversubscribed private placement to fund its Phase 3 clinical trials and general operations.

Tenax Therapeutics has increased the number of shares available under its stock incentive plan and amended its Chief Medical Officer's employment agreement to reflect a reduced work schedule.

Tenax Therapeutics announced its first quarter 2024 financial results, highlighted by the initiation of its Phase 3 LEVEL study for PH-HFpEF and securing global rights for levosimendan.

Tenax Therapeutics announced the first patient enrollment in its Phase 3 LEVEL trial for TNX-103, secured global commercial rights for levosimendan in PH-HFpEF, and provided full year 2023 financial results.

Tenax Therapeutics has regained compliance with Nasdaq listing rules after demonstrating it has over 500,000 publicly held shares.

Tenax Therapeutics has broadened its license agreement with Orion Corporation, obtaining worldwide rights to develop and commercialize levosimendan-based products, excluding neurological applications.

Tenax Therapeutics has successfully priced a public offering to raise approximately $9 million, which will be used to advance its Phase 3 trial of oral levosimendan and for general corporate purposes.